SCHEMBL14923005

SCHEMBL14923005

CNC(=O)c1cc(Oc2ccc(NC(C)=O)c(F)c2)ccn1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 5/20 0.63
MAPK14 Q16539 9/20 0.62
KDR P35968 7/20 0.62
RAF1 P04049 6/20 0.62
BRAF P15056 6/20 0.62
RET P07949 4/20 0.62
MAP3K20 Q9NYL2 4/20 0.62
RIPK2 O43353 3/20 0.62
EPHX2 P34913 3/20 0.62
KIT P10721 3/20 0.62
FGFR1 P11362 3/20 0.62
PDGFRA P16234 3/20 0.62
FLT1 P17948 3/20 0.62
EPHA1 P21709 3/20 0.62
TTK P33981 3/20 0.62
FLT4 P35916 3/20 0.62
FLT3 P36888 3/20 0.62
CLK1 P49759 3/20 0.62
LIMK1 P53667 3/20 0.62
CDK17 Q00537 3/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14911164 0.92 ABL1 (0.73) ABL1MAPK14KDRRAF1BRAF
SCHEMBL19888749 0.86 ABL1 (0.67) ABL1MAPK14KDRRAF1BRAF
SCHEMBL19888723 0.86 ABL1 (0.59) ABL1MAPK14KDRRAF1BRAF
SCHEMBL10163140 0.86 KDR (0.55) ABL1MAPK14KDRRAF1BRAF
SCHEMBL29834780 0.85 ABL1 (0.64) ABL1MAPK14KDRRAF1BRAF
SCHEMBL17914280 0.85 ABL1 (0.57) ABL1MAPK14KDRRAF1BRAF
SCHEMBL2560625 0.85 BRAF (0.59) ABL1MAPK14KDRRAF1BRAF
SCHEMBL17471735 0.85 RAF1 (0.59) ABL1MAPK14KDRRAF1BRAF
SCHEMBL19888732 0.85 RIPK2 (0.70) ABL1MAPK14KDRRAF1BRAF
SCHEMBL19888717 0.85 ABL1 (0.65) ABL1MAPK14KDRRAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016203352-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER MOHAN M ALAPATI (IN) 2016-12-22 WO disclosed
WO-2016203337-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER MOHAN M ALAPATI (IN) 2016-12-22 WO disclosed
EP-2589384-A1 New Pharmaceutical Compositions for the Treatment of Hyper-Proliferative Disorders Bayer Healthcare LLC (US) 2013-05-08 EP disclosed